PD-1 |
Nivolumab |
Bristol-Meyers Squibb Company Inc. |
Metastatic small cell lung cancer |
|
Progression after platinum-based chemotherapy and at least one other line of therapy |
August 16, 2018 |
[151] |
|
|
Metastatic colorectal cancer |
Ipilimumab |
Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) |
July 10, 2018 |
[152] |
|
|
Untreated advanced renal cell carcinoma |
Ipilimumab |
|
April 16, 2018 |
[153] |
|
|
Melanoma |
Adjuvant treatment |
Involvement of lymph nodes |
December 20, 2017 |
[154] |
|
|
Hepatocellular carcinoma |
|
|
September 22, 2017 |
[155] |
|
|
Metastatic colorectal cancer |
|
Mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H) |
July 31, 2017 |
[156] |
|
|
Locally advanced or metastatic urothelial carcinoma |
|
|
February 2, 2017 |
[157] |
|
|
Squamous cell carcinoma of the head and neck |
|
|
November 10, 2016 |
[158] |
|
|
Classic Hodgkin lymphoma |
|
|
May 17, 2016 |
[159] |
|
|
Advanced renal cell carcinoma |
|
|
November 23, 2015 |
[160] |
|
|
Metastatic non-small cell lung cancer |
|
|
October 9, 2015 |
[161] |
|
|
Metastatic melanoma |
Ipilimumab |
BRAF V600 wild type |
September 30, 2015 |
[162] |
|
|
Metastatic squamous non-small cell lung cancer |
|
|
March 4, 2015 |
[163] |
|
|
Unresectable or metastatic melanoma |
|
|
December 22, 2014 |
[164] |
Pembrolizumab |
Merck & Co, Inc. |
Non-small cell lung cancer |
Carboplatin and either paclitaxel or nab-paclitaxel |
|
October 30, 2018 |
[165] |
|
|
Metastatic, non-squamous non-small cell lung cancer |
Pemetrexed and platinum |
|
August 20, 2018 |
[166] |
|
|
Primary mediastinal large B cell lymphoma |
|
|
June 13, 2018 |
[167] |
|
|
Metastatic cervical cancer |
|
Express PD-L1 (combined positive score ≥ 1) |
June 12, 2018 |
[168] |
|
|
Gastric or gastroesophageal junction adenocarcinoma |
|
Express PD-L1 |
September 22, 2017 |
[169] |
|
|
Solid tumors |
|
Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) |
May 23, 2017 |
[170] |
|
|
Urothelial carcinoma |
|
|
May 18, 2017 |
[171] |
|
|
Metastatic non-squamous non-small cell lung cancer |
Pemetrexed and carboplatin |
|
May 10, 2017 |
[172] |
|
|
Classic Hodgkin lymphoma |
|
|
March 14, 2017 |
[173] |
|
|
Metastatic non-small cell lung cancer |
|
Express PD-L1 |
October 24, 2016 |
[174] |
|
|
Recurrent or metastatic head and neck squamous cell carcinoma |
|
|
August 5, 2016 |
[175] |
|
|
Unresectable or metastatic melanoma |
|
|
December 18, 2015 |
[176] |
|
|
Metastatic non-small cell lung cancer |
|
Express PD-L1 |
October 2, 2015 |
[177] |
|
|
Unresectable or metastatic melanoma |
|
Following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor |
September 4, 2014 |
[178] |
PD-L1 |
Atezolizumab |
Genentech Oncology |
Metastatic non-small cell lung cancer |
|
|
October 18, 2016 |
[179] |
|
|
Locally advanced or metastatic urothelial carcinoma |
|
|
May 18, 2016 |
[180] |
Durvalumab |
AstraZeneca Inc. |
Stage III non-small cell lung cancer |
|
|
February 16, 2018 |
[181] |
|
|
Locally advanced or metastatic urothelial carcinoma |
|
|
May 1, 2017 |
[182] |
Avelumab |
EMD Serono, Inc. |
Metastatic Merkel cell carcinoma |
|
|
March 23, 2017 |
[183] |
CTLA-4 |
Ipilimumab |
Bristol-Meyers Squibb Company, Inc. |
Metastatic colorectal cancer |
Nivolumab |
Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) |
July 10, 2018 |
[152] |
|
|
Untreated advanced renal cell carcinoma |
Nivolumab |
|
April 16, 2018 |
[153] |
|
|
Cutaneous melanoma |
|
|
October 28, 2015 |
[184] |
|
|
BRAF V600 wild-type, unresectable or metastatic melanoma |
Nivolumab |
|
September 30, 2015 |
[162] |